Department of Pancreato-Biliary Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
Department of Pancreato-Biliary Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
Int Immunopharmacol. 2024 Nov 15;141:112917. doi: 10.1016/j.intimp.2024.112917. Epub 2024 Aug 12.
This study aimed to explore novel targets for hepatocellular carcinoma (HCC) treatment by investigating the role of fatty acid metabolism.
RNA-seq and clinical data of HCC were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Bioinformatic analyses were employed to identify differentially expressed genes (DEGs) related to prognosis. A signature was then constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression to classify HCC patients from the TCGA database into low-risk and high-risk groups. The predictive performance of the signature was evaluated through principal components analysis (PCA), Kaplan Meier (KM) survival analysis, receiver operating characteristics (ROC) curves, nomogram, genetic mutations, drug sensitivity analysis, immunological correlation analysis, and enrichment analysis. Single-cell maps were constructed to illustrate the distribution of core genes. Immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR), and western blot were employed to verify the expression of core genes. The function of one core gene was validated through a series of in vitro assays, including cell viability, colony formation, wound healing, trans-well migration, and invasion assays. The results were analyzed in the context of relevant signaling pathways.
Bioinformatic analyses identified 15 FAMGs that were related to prognosis. A 4-gene signature was constructed, and patients were divided into high- and low-risk groups according to the signature. The high-risk group exhibited a poorer prognosis compared to the low-risk group in both the training (P < 0.001) and validation (P = 0.020) sets. Furthermore, the risk score was identified as an independent predictor of OS (P < 0.001, HR = 8.005). The incorporation of the risk score and clinicopathologic features into a nomogram enabled the effective prediction of patient prognosis. The model was able to effectively predict the immune microenvironment, drug sensitivity to chemotherapy, and gene mutation for each group. Single-cell maps demonstrated that FAMGs in the model were distributed in tumor cells. Enrichment analyses revealed that the cell cycle, fatty acid β oxidation and PPAR signaling pathways were the most significant pathways. Among the four key prognostically related FAMGs, Spermine Synthase (SMS) was selected and validated as a potential oncogene affecting cell cycle, PPAR-γ signaling pathway and fatty acid β oxidation in HCC.
The risk characteristics based on FAMGs could serve as independent prognostic indicators for predicting HCC prognosis and could also serve as evaluation criteria for gene mutations, immunity, and chemotherapy drug therapy in HCC patients. Meanwhile, targeted fatty acid metabolism could be used to treat HCC through related signaling pathways.
本研究旨在通过研究脂肪酸代谢来探索肝细胞癌(HCC)治疗的新靶点。
从基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)数据库中获取 HCC 的 RNA-seq 和临床数据。采用生物信息学方法分析与预后相关的差异表达基因(DEGs)。然后使用最小绝对值收缩和选择算子(LASSO)Cox 回归构建signature,用于将 TCGA 数据库中的 HCC 患者分为低风险和高风险组。通过主成分分析(PCA)、Kaplan-Meier(KM)生存分析、受试者工作特征(ROC)曲线、列线图、遗传突变、药物敏感性分析、免疫相关性分析和富集分析评估signature 的预测性能。构建单细胞图谱以说明核心基因的分布。免疫组织化学(IHC)、实时定量 PCR(qRT-PCR)和 Western blot 用于验证核心基因的表达。通过一系列体外实验,包括细胞活力、集落形成、划痕愈合、Transwell 迁移和侵袭实验,验证了一个核心基因的功能。并在相关信号通路的背景下分析了结果。
生物信息学分析确定了 15 个与预后相关的 FAMGs。构建了一个 4 基因 signature,并根据 signature 将患者分为高风险和低风险组。在训练集(P<0.001)和验证集(P=0.020)中,高风险组的预后均明显差于低风险组。此外,风险评分被确定为 OS 的独立预测因子(P<0.001,HR=8.005)。将风险评分和临床病理特征纳入列线图可有效预测患者的预后。该模型能够有效地预测各组的免疫微环境、化疗药物敏感性和基因突变。单细胞图谱表明模型中的 FAMGs 分布在肿瘤细胞中。富集分析表明细胞周期、脂肪酸β氧化和 PPAR 信号通路是最重要的通路。在与预后相关的四个关键 FAMGs 中,精脒合成酶(SMS)被选择并验证为影响 HCC 细胞周期、PPAR-γ 信号通路和脂肪酸β氧化的潜在癌基因。
基于 FAMGs 的风险特征可作为独立的预测 HCC 预后的指标,并可作为 HCC 患者基因突变、免疫和化疗药物治疗的评估标准。同时,通过相关信号通路靶向脂肪酸代谢可能用于治疗 HCC。